13 results about "Cilium" patented technology

The invention belongs to the technical field of bionic cilium sensors, and particularly discloses a magnetic bionic cilium and vesicle complex and a preparation method and application thereof.The preparation method comprises the following steps that S1, a cilium array male mold is prepared; then carrying out oxygen plasma treatment, silanization and curing stabilization; s3, injecting the magnetic composite precursor into a polydimethylsiloxane female die, applying pressure, and striking off; and S4, coating the mold surface with an Ecoflex precursor, performing thermocuring forming, performing magnetization treatment, and performing stripping to obtain the magnetic bionic cilia. According to the magnetic bionic cilia, the vesicle complex and the preparation method and application of the magnetic bionic cilia, the vesicle complex and the preparation method and application of the magnetic bionic cilia, high-magnetic signal output is achieved while the deformability of the cilia is guaranteed, the magnetic bionic cilia is used for non-contact real-time hemodynamic monitoring, meanwhile, specific response release of the vesicle complex is achieved, and a new thought is provided for design of responsive vascular implants.

The invention relates to a postoperative anti-regurgitation self-cleaning drainage tube which is suitable for chest drainage after pulmonary lobectomy. In order to solve the problems that a traditional drainage tube depends on gravity to conduct passive drainage, a tube cavity is prone to forming a biological membrane due to sediment to cause blockage and drainage efficiency is insufficient, a plurality of cilia are arranged on the inner wall of a drainage tube body in a surrounding mode in the circumferential direction, the sizes of the cilia are gradually reduced from the root to the top end, and the elasticity modulus is reduced in a gradient mode in the drainage direction; and the vibration device is matched to drive the cilia to swing directionally in the same direction as the drainage direction. According to the design, by simulating the respiratory tract cilia function and utilizing the synergistic effect of cilia structural characteristics and vibration excitation, tube wall sediments are actively and physically stripped, a biological membrane is destroyed to form a foundation, and meanwhile, cilia directionally swings to form drainage auxiliary thrust. According to the application, the occurrence rate of lumen blockage can be obviously reduced, the drainage efficiency is improved, the postoperative pain and medical cost of a patient are reduced, the recovery period is shortened, and the clinical efficient drainage and anti-blockage requirements are met.

The present invention relates to a method for producing respiratory organoids by proliferating and differentiating respiratory epithelial cells. [Solution] Unlike conventional respiratory organoids in which epithelial cells present at the apical end of the respiratory tract develop inside the organoid, the respiratory organoid of the present invention has a morphology in which the ciliated structure, which is made up of epithelial cells, is located in the outer layer of the organoid, secretory cells are located inside, and stem cell-like basal cells present at the base of the respiratory tissue are also located inside the organoid. This morphology is similar to that of actual respiratory tissue and has been observed to exhibit normal functions of epithelial cells, such as the motility of ciliated cells. Therefore, by manufacturing organoids using the manufacturing method of the present invention, it is possible to manufacture respiratory organoids that can accurately mimic actual tissue.

The invention relates to application of PDCD5 in preparation of a diagnostic agent or a therapeutic agent for asthenospermia. The invention also discloses a method for constructing an asthenospermia mouse model or inhibiting fibroblast cilia generation by knocking out or knocking down the PDCD5. The application shows that PDCD5 participates in sperm generation, and asthenozoospermia can be caused if the PDCD5 has function deletion mutation in testis. Therefore, the gene locus can be used as a target spot for asthenospermia diagnosis and medication guidance. According to the method disclosed by the invention, the dysfunction of the site is supplemented by the PDCD5 RNA wrapped by the testis injection liposome, so that the asthenospermia caused by the mutation is rescued, the sperm quantity is increased, the sperm malformation rate is reduced, and a new path is provided for the treatment of the asthenospermia.

To provide a method for preparing a respiratory organoid by proliferating and differentiating respiratory epithelial cells.SOLUTION: Unlike conventional respiratory organoids in which epithelial cells existing in an apical region of a respiratory organ are generated on an interior of the organoid, the respiratory organoid of the present disclosure is shown in a form in which ciliated structures, which are epithelial cells, are located in an outer layer of the organoid, secretory cells are present on the interior, and basal stem cells existing at a base of respiratory tissue are also present on the interior of the organoid. It has a form similar to an actual respiratory tissue, and it was observed to exhibit normal functions of the epithelial cells, such as motility of ciliated cells. Therefore, when an organoid is prepared using the preparation method of the present disclosure, a respiratory organoid that can well mimic the actual tissue can be prepared.SELECTED DRAWING: Figure 1

The invention relates to the field of biological medicine, in particular to application of kaempferol in preparation of a medicine for promoting cilia growth, and provides application of kaempferol or pharmaceutically acceptable salt, stereoisomer, solvate, prodrug or derivative thereof in preparation of the medicine for promoting cilia growth. And a pharmaceutical composition or combination comprising a therapeutically effective amount of kaempferol or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug or derivative thereof.

Disclosed are methods and systems for modifying the motility of engineered multicellular organisms. The engineered multicellular organisms include an aggregate of cells, e.g., ciliated cells. The methods may include exposing the engineered multicellular organism to an acoustic stimulation, e.g., sound at a frequency of about 5 Hz to about 1000 Hz.

The present application provides an inhibitor of primary cilium of an immune-related cell and an application thereof. The solution is to use an inhibitor of primary cilium of an immune-related cell containing an ERK1 / 2 inhibitor as an effective component.

The invention provides a Matrigel-free everted cilia organ and a culture method and application thereof.According to the method, a serum-free BPE-free amplification system, a Matrigel-free everted cilia organ and a high-throughput compatible culture method and an everted cilia differential medium are adopted, a culture system with definite chemical components is adopted for non-invasive sampling of a nasal swab, matrigel is not needed, and the Matrigel-free everted cilia organ is obtained. According to the method, the culture mode that the 96U-shaped bottom ultra-low adsorption pore plate / Agrrewell pore plate / cell ball honeycomb sheet pore plate is adopted for 3D differentiation culture to form the organoid is adopted, the purposes of completing amplification and cilia differentiation in a low-cost, standardized and high-throughput mode are achieved, and a feasible path is provided for subsequent large-scale drug screening and individualized precise diagnosis and treatment.

Disclosed are methods of using multicellular constructs in methods to detect anti-aging or pro-regenerative compositions. The disclosed organisms comprise an aggregate of ciliated cells, and the organisms move when the ciliated cells are actuated. Also disclosed are populations of motile multicellular constructs with improved longevity, methods of generating motile multicellular constructs with improved longevity, and methods of reducing the cellular age of a sample of ciliated epithelial cells.

The invention relates to the skipping of the CEP290 exon 36 in an individual suffering from a retinal dystrophy accounted for by a nonsense mutation or a premature termination codon generated by a frameshift mutation in exon 36 or an upstream exon, including the c.4723A>T, c.4771C>T, c.4714G>T, c.4786_4790del, c.4791_4794del, c.4732G>T, c.4625_4626insCATG (35), c.4792_4795del, c.4801C>T, c.4805C>T, or c.4811G>A mutations, to bypass protein truncation and lessen retinal damages. Here, studying fibroblasts from control individuals, and two patients carrying the CEP290 c.4723A>T nonsense mutation, they show low levels of spontaneous skipping of exon 36 arising from both endogenous basal skipping and mutation-induced skipping. The minimally shortened and mutation-free CEP290 mRNA produced by skipping of exon 36 in the fibroblasts of the two patients is translated into a protein isoform that localizes at the centrosome and allows the formation of primary cilia, yet with elongated axonemes. Using an AON consisting of a sequence set forth as SEQ ID NO: 1, complementary to a nucleic acid sequence of CEP290 pre-mRNA, wherein said AON targeting an mRNA encoding the donor splice site (H36D) is capable to alter splicing by blocking the recognition of exon 36 and bypass protein truncation while maintaining the open reading frame, leading to the production of near full-length CEP290 protein, they were able to increase the abundance of the alternatively spliced mRNA and shortened protein and to reduce axonemal length in patient cells.

The invention provides a construction method and application of a bifluorescence reporter gene animal model for tracking transdifferentiation from airway cilia cells to mucous cells. A transgenic animal model capable of specifically and permanently marking and tracking airway ciliary cell fate transformation is constructed by utilizing a Cre-LoxP gene recombinase system and combining with double promoters and double fluorescence reporter genes. In the progeny, normal cilia cells only express GFP (green). When the cell starts to express MUC5AC under external stimulation (such as PM2.5 and allergen), the existing Cre recombinase in the cell nucleus can recognize and cut off the loxP-Stop-loxP sequence at the downstream of the MUC5AC gene, so that the expression of the RFP gene is started. Finally, mucus-cilia cells obtained by transdifferentiation of cilia cells can simultaneously express GFP (green fluorescent protein) and RFP (yellow), or only express RFP (red) after completely losing cilia cell characteristics. The irreversible color conversion provides a definite evidence for the'provenance and today 'of the cells.